A retrospective cohort study of 124 men with biopsy Gleason 6 prostate cancer found that elevated PSA density and perineural ...
A phase 3 PROTEUS substudy published in European Urology reports that perioperative apalutamide plus hormone therapy around ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
What’s New On Radiotherapy of Prostate Cancer in 2026? / OncoDaily RT, prostate cancer, prostate cancer radiotherapy, ...
Proud to Share New PROTEUS Findings on Perioperative Treatment in High-Risk Prostate Cancer / A Douglas Laird, ADT, Alberto ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...
MedPage Today on MSN
Lower metastasis risk in very high-risk prostate cancer with intensified treatment
Adding darolutamide to ADT and RT improved metastasis-free survival, but questions persist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results